S
Shafika Kasem
Researcher at Hebrew University of Jerusalem
Publications - 3
Citations - 2831
Shafika Kasem is an academic researcher from Hebrew University of Jerusalem. The author has contributed to research in topics: Prostate cancer & Carcinogen. The author has an hindex of 3, co-authored 3 publications receiving 2646 citations.
Papers
More filters
Journal ArticleDOI
NF-κB functions as a tumour promoter in inflammation-associated cancer
Eli Pikarsky,Rinnat M. Porat,Ilan Stein,Rinat Abramovitch,Sharon Amit,Shafika Kasem,Elena Gutkovich-Pyest,Simcha Urieli-Shoval,Eithan Galun,Yinon Ben-Neriah +9 more
TL;DR: It is shown that the inflammatory process triggers hepatocyte NF-κB through upregulation of tumour-necrosis factor-α (TNFα) in adjacent endothelial and inflammatory cells, and is therefore a potential target for cancer prevention in chronic inflammatory diseases.
Journal ArticleDOI
Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis
Merav Darash-Yahana,Eli Pikarsky,Rinat Abramovitch,Evelyne Zeira,Boaz Pal,Rebekah Karplus,Katia Beider,Shani Avniel,Shafika Kasem,Eithan Galun,Amnon Peled +10 more
TL;DR: High levels of the chemokine receptor CX CR4 induce a more aggressive phenotype in prostate cancer cells and identify CXCR4 as a potential therapeutic target in advanced cases of metastatic prostate cancer.
Journal ArticleDOI
Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts.
Mirela Goldenberg-Furmanov,Ilan Stein,Eli Pikarsky,Hila Rubin,Shafika Kasem,Marc R. Wygoda,Irina Weinstein,Hadas Reuveni,Shmuel A. Ben-Sasson +8 more
TL;DR: It is suggested that Lyn inhibition may serve as a prime target for the treatment of hormone-refractory PC after a Lyn-specific inhibitor, KRX-123, targeting a unique interaction site within Lyn was synthesized.